DK2968457T3 - Faktor h til transplantation - Google Patents

Faktor h til transplantation Download PDF

Info

Publication number
DK2968457T3
DK2968457T3 DK14721085.0T DK14721085T DK2968457T3 DK 2968457 T3 DK2968457 T3 DK 2968457T3 DK 14721085 T DK14721085 T DK 14721085T DK 2968457 T3 DK2968457 T3 DK 2968457T3
Authority
DK
Denmark
Prior art keywords
factor
composition
allograft
recipient
rejection
Prior art date
Application number
DK14721085.0T
Other languages
English (en)
Inventor
Richard Johnson
Jenny Zheng Zhang
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Application granted granted Critical
Publication of DK2968457T3 publication Critical patent/DK2968457T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01002—Fumarate hydratase (4.2.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Sammensætning omfattende Faktor H (FH) til anvendelsen i en fremgangsmåde til at forebygge eller inhibere allograft-afstødning afen modtager af nævnte allograft, hvor nævnte modtager yderligere behandles med en første immunhæmmende sammensætning omfattende et element valgt fra sirolimus (Rapamycin), FK506 (FK), cyclosporin, og tacrolimus.
2. Sammensætningen ifølge krav 1, til anvendelsen ifølge krav 1, hvor nævnte FH er plasma-afledt FH eller rekombinant FH.
3. Sammensætningen ifølge krav 1 eller krav 2, til anvendelsen ifølge krav 1 eller krav 2, hvor nævnte modtager yderligere behandles med et andet forskelligt immunhæmmende middel omfattende et element uafhængigt valgt fra sirolimus (Rapamycin), FK506 (FK), cyclosporin, og tacrolimus.
4. Sammensætningen ifølge kravene 1-3, til anvendelsen ifølge kravene 1-3, hvor nævnte fremgangsmåde omfatter behandling af nævnte modtager med en sammensætning omfattende FH, en sammensætning omfattende FK, og en sammensætning omfattende Rapamycin.
5. Sammensætningen ifølge kravene 1-4, til anvendelsen ifølge kravene 1-4, hvor nævnte allograft-afstødning er en antistof-medieret afstødning eller en kombination af antistof- og celle-medieret afstødning.
6. Sammensætningen ifølge kravene 1-5, til anvendelsen ifølge kravene 1-5, hvor nævnte forebyggelse eller inhibering af allograft-afstødning omfatter at forlænge allograft-overlevelse og/eller -funktion i et forudbestemt antal dage.
7. Sammensætningen ifølge kravene 1-6, til anvendelsen ifølge kravene 1-6, hvor nævnte forebyggelse eller inhibering af allograft-afstødning omfatter forebyggelse eller inhibering af en stigning i niveauer af markører for allograft-afstødning.
8. Sammensætningen ifølge kravene 1-7, til anvendelsen ifølge kravene 1-7, hvor nævnte allograft-afstødning er akut antistof-medie ret afstødning.
9. Sammensætningen ifølge krav 7, til anvendelsen ifølge krav 7, hvor nævnte modtager behandles med FH ved modtagelse af nævnte allograft, indtil nævnte allograft fungerer normalt.
10. Sammensætningen ifølge krav 9, til anvendelsen ifølge krav 9, hvor normal funktion af nævnte allograft bestemmes ved modtager-kreatinniveau og/eller negativ C4d-biopsi-testning.
11. Sammensætningen ifølge kravene 1-7, til anvendelsen ifølge kravene 1-7, hvor nævnte allograft-afstødning forekommer 3-6 måneder efter modtagelse af nævnte allograft.
12. Sammensætningen ifølge kravene 1-11, til anvendelsen ifølge kravene 1-11, hvor nævnte allograft omfatter et organ eller væv.
13. Sammensætningen ifølge krav 12, til anvendelsen ifølge krav 12, hvor nævnte organ er et helt organ.
14. Sammensætningen ifølge krav 13, til anvendelsen ifølge krav 13, hvor nævnte hele organ er et element valgt fra nyre, hjerte, lever, tarm, bugspytkirtel og lunge.
15. Sammensætningen ifølge kravene 1-11, til anvendelsen ifølge kravene 1-11, hvor nævnte allograft er et element valgt fra en hudgraft, en knoglegraft, en hjerteklap, og knoglemarv.
DK14721085.0T 2013-03-14 2014-03-13 Faktor h til transplantation DK2968457T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785977P 2013-03-14 2013-03-14
PCT/US2014/026677 WO2014151919A1 (en) 2013-03-14 2014-03-13 Factor h for transplantation

Publications (1)

Publication Number Publication Date
DK2968457T3 true DK2968457T3 (da) 2018-10-29

Family

ID=50631029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14721085.0T DK2968457T3 (da) 2013-03-14 2014-03-13 Faktor h til transplantation

Country Status (14)

Country Link
US (1) US9138466B2 (da)
EP (1) EP2968457B1 (da)
JP (1) JP6373963B2 (da)
AU (1) AU2014236778B2 (da)
CA (1) CA2906527A1 (da)
DK (1) DK2968457T3 (da)
ES (1) ES2703382T3 (da)
HR (1) HRP20181451T1 (da)
HU (1) HUE039464T2 (da)
LT (1) LT2968457T (da)
PL (1) PL2968457T3 (da)
PT (1) PT2968457T (da)
SI (1) SI2968457T1 (da)
WO (1) WO2014151919A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3526249A4 (en) * 2016-10-17 2020-07-01 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TRANSPLANT-ASSOCIATED LESION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
WO2000052479A2 (en) 1999-03-05 2000-09-08 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
AU6110301A (en) 2000-04-29 2001-11-12 Univ Iowa Res Found Diagnostics and therapeutics for macular degeneration-related disorders
WO2006062716A2 (en) 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
CN101563363B (zh) * 2006-06-21 2013-01-02 南卡罗来纳医疗大学研究发展基金会 用于治疗疾病的靶向补体因子h
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
CN109045296A (zh) * 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
AT514675B1 (de) * 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
WO2012095519A1 (en) * 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation

Also Published As

Publication number Publication date
WO2014151919A1 (en) 2014-09-25
HRP20181451T1 (hr) 2018-12-28
SI2968457T1 (sl) 2018-11-30
EP2968457A1 (en) 2016-01-20
US20140335113A1 (en) 2014-11-13
AU2014236778A1 (en) 2015-10-15
PT2968457T (pt) 2018-11-07
US9138466B2 (en) 2015-09-22
JP6373963B2 (ja) 2018-08-15
EP2968457B1 (en) 2018-08-29
JP2016514158A (ja) 2016-05-19
ES2703382T3 (es) 2019-03-08
CA2906527A1 (en) 2014-09-25
PL2968457T3 (pl) 2018-12-31
HUE039464T2 (hu) 2019-01-28
LT2968457T (lt) 2018-10-25
AU2014236778B2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
EP2563384B1 (en) Immunogenic compositions for treating neoplasia
EP2976094B1 (en) Methods of treating metabolic disorders
JP2016518357A (ja) 骨格筋幹細胞を若返らせる方法および組成物
AU2005239913B2 (en) Medicament for the treatment of fungal infections, particularly aspergillosis
WO2008118370A2 (en) Hyperbaric treatment in wound healing
EP2964774B1 (en) Ptd-smad7 therapeutics
DK2968457T3 (da) Faktor h til transplantation
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
US9248162B2 (en) Factor H for treatment of rheumatoid arthritis
HUE035446T2 (en) For use in the treatment of parathyroid hormone (PTH) ischemia
AU2018244776B2 (en) Methods of treatment for kidney disease
Sommerfeld et al. Biomaterials-based immunomodulation enhances survival of murine vascularized composite allografts
US20240181135A1 (en) Biochemical activation of dysfunctional skeletal stem cells for skeletal regeneration
Kulak Innate immunity in diabetes mellitus. Complement components C4BP and C3 promote survival of β cells under metabolic challenges.
WO2023064373A1 (en) Targeting slc46a2-mediated muropeptide transport to treat psoriasis
WO2022170396A1 (en) Agents and methods for therapy and prophylaxis
Van Beusecum The Functional Role of Toll-like Receptor 4 in the Renal Microcirculation.
WO2011156715A2 (en) Methods of treating metabolic disorders and cardiovascular diseases
Kontny et al. SAT0047 The origin and biological activities of classical adipokines in rheumatoid joint